C.E. Credits

The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


MAY 8 - 9 2019

Genetics & Genomics 2019



 

Our 7th Annual Genetics and Genomics Virtual Event is now available On-Demand! The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.

Topic's for this years event included: 

  • Progress in Genome Editing Including Single Base Editing and Application
  • Interpreting Genome Sequence Information from Telomere to Telomere
    • What does GWAS really tell you about targets for drug discovery
  • Chromosomal Instability, Somatic Cell Recombination and Genomic Stability
  • The Epigenome in Health and Disease
  • Polygenic Risk Scores: PheWas and GWAS and Utility of Biobank Information

 

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 32 credits.

Additionally, the National Society of Genetic Counselors (NSGC) has authorized LabRoots  to offer up to 0.6 CEUs or 6 Category 1 contact hours for the activity 2019 Genetics & Genomics virtual event. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

Please click on the CE/CEU tab to view those presentations approved for PACE CE and CEU's.

Use #LRgenetics to follow the conversation!


Speakers
  • Professor of Genetics, Director of the Center for Computational Genetics, Harvard Medical School
  • Professor and Chair, Genetics, Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
  • Global Market Development Scientist, Gene Editing and Novel Modalities, MilliporeSigma
  • Professor and Senior Vice President, Sanford Burnham Prebys Medical Discovery Institute
  • R&D Scientist, MilliporeSigma
  • Head of Science, Synthego
  • Senior R&D Scientist, MilliporeSigma
  • CSO, Vivlion
  • Co-Founder and Chief Science Officer, Genomenon
  • Chief Scientific Officer, Pacific Biosciences
  • Assistant Research Scientist, Department of Biomolecular Engineering, University of California, Santa Cruz
  • Senior Field Application Scientist, QIAGEN Advanced Genomics
  • Associate Professor, Director, Genetic and Molecular Epidemiology Laboratory, McMaster Genome Institute
  • Professor of Computational Biology and Bioinformatics, Chair of the Department of Biostatistics, Harvard University, Dana-Farber Cancer Institute
  • Harry P. Schenck Endowed Chair Professor, Vice-Chair, Department of Otorhinolaryngology, Perelman School of Medicine, University of Pennsylvania
  • Associate Director, NGS Assay Technologies, QIAGEN
  • Faculty Investigator, HudsonAlpha Institute for Biotechnology
  • Assistant Professor, CPRIT Scholar for Cancer Research, Department of Molecular and Human Genetics, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine

Show Resources
You May Also Like
NOV 14, 2019 06:00 AM PST
C.E. CREDITS
NOV 14, 2019 06:00 AM PST
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2019 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
AUG 22, 2019 06:00 AM PDT
C.E. CREDITS
AUG 22, 2019 06:00 AM PDT
LabRoots is pleased to announce a new addition to our virtual conference line up for 2019, Forensics & Toxicology! The exciting field of Forensics/Toxicology is focused on a blend of biology...
JUN 20, 2019 06:00 AM PDT
C.E. CREDITS
JUN 20, 2019 06:00 AM PDT
LabRoots and the Precision Medicine Planning Committee are pleased to announce the 4th Annual Precision Medicine Virtual Event. Precision Medicine 2019, a two-day event held June 19-20, will...
SEP 26, 2019 06:00 AM PDT
C.E. CREDITS
SEP 26, 2019 06:00 AM PDT
LabRoots and the Cell Biology Planning Committee are please to announce the 3rd Annual Cell Biology Virtual Event, providing an opportunity to discuss recent discoveries in biological researc...
NOV 12, 2020 06:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 06:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
SEP 11, 2019 06:00 AM PDT
C.E. CREDITS
SEP 11, 2019 06:00 AM PDT
LabRoots and the Microbiology Planning Committee is bringing the microbiology research community together at the 5th Annual Microbiology and Immunology Virtual Event! During the free, two-day...
Agenda
  • MAY 08, 2019 06:00 AM PDT
    Speaker: Tao Wu, PhD
  • MAY 08, 2019 06:00 AM PDT
    Sponsored By: MilliporeSigma
    Michelle Ding, M.S.
    R&D Scientist, MilliporeSigma
    Yanfang Jiang, PhD
    Senior R&D Scientist, MilliporeSigma
  • MAY 08, 2019 07:30 AM PDT
    Speaker: George Church, PhD
  • MAY 08, 2019 09:00 AM PDT
    Speaker: Manuel Kaulich, PhD
  • MAY 08, 2019 09:00 AM PDT
    Speaker: Kevin Holden, PhD
    Sponsored By: Synthego
  • MAY 08, 2019 10:30 AM PDT
    Speaker: Devendra Mistry, PhD
    Sponsored By: QIAGEN
  • MAY 08, 2019 10:30 AM PDT
    Speaker: John Quackenbush, PhD
  • MAY 08, 2019 12:00 PM PDT
    Speaker: Jonathan Shaffer, MBA, PhD
    Sponsored By: QIAGEN
  • MAY 08, 2019 01:30 PM PDT
    Speaker: Jonas Korlach, PhD
    Sponsored By: PacBio
  • MAY 09, 2019 06:00 AM PDT
    Speaker: Mark Kiel, MD, PhD
  • MAY 09, 2019 07:30 AM PDT
    Speaker: Michael Snyder, PhD
  • MAY 09, 2019 09:00 AM PDT
    Speaker: Karen Miga, PhD
  • MAY 09, 2019 09:00 AM PDT
    Polygenic Risk Scores: PheWas and GWAS and Utility of Biobank Information
    Speaker: Guillaume Paré, MD, MSc, FRCPC
    Sponsored By: Illumina
  • MAY 09, 2019 10:30 AM PDT
    Speaker: Gillian Browne, PhD
    Sponsored By: MilliporeSigma
  • MAY 09, 2019 10:30 AM PDT
    Speaker: Jerold Chun, MD, PhD
  • MAY 09, 2019 12:00 PM PDT
    A Metagenomic Assay to Interrogate the Role of Virome and Microbiome in Cancer
    Speaker: Erle Robertson, PhD
    Sponsored By: Agilent
  • MAY 09, 2019 01:30 PM PDT
    Speaker: Liz Worthey, PhD
  • The Epigenome in Health and Disease
  • MAY 08, 2019 06:00 AM PDT
    Speaker: Tao Wu, PhD
  • MAY 09, 2019 07:30 AM PDT
    Speaker: Michael Snyder, PhD
  • Progression in Genome Editing Including Single Base Editing and Application
  • MAY 08, 2019 06:00 AM PDT
    Sponsored By: MilliporeSigma
    Michelle Ding, M.S.
    R&D Scientist, MilliporeSigma
    Yanfang Jiang, PhD
    Senior R&D Scientist, MilliporeSigma
  • MAY 08, 2019 10:30 AM PDT
    Speaker: Devendra Mistry, PhD
    Sponsored By: QIAGEN
  • Interpreting Genome Sequence Information from Telomere to Telomere
  • MAY 08, 2019 07:30 AM PDT
    Speaker: George Church, PhD
  • MAY 08, 2019 09:00 AM PDT
    Speaker: Kevin Holden, PhD
    Sponsored By: Synthego
  • MAY 08, 2019 10:30 AM PDT
    Speaker: John Quackenbush, PhD
  • MAY 08, 2019 12:00 PM PDT
    Speaker: Jonathan Shaffer, MBA, PhD
    Sponsored By: QIAGEN
  • MAY 08, 2019 01:30 PM PDT
    Speaker: Jonas Korlach, PhD
    Sponsored By: PacBio
  • MAY 09, 2019 06:00 AM PDT
    Speaker: Mark Kiel, MD, PhD
  • MAY 09, 2019 09:00 AM PDT
    Speaker: Karen Miga, PhD
  • MAY 09, 2019 10:30 AM PDT
    Speaker: Gillian Browne, PhD
    Sponsored By: MilliporeSigma
  • MAY 09, 2019 12:00 PM PDT
    A Metagenomic Assay to Interrogate the Role of Virome and Microbiome in Cancer
    Speaker: Erle Robertson, PhD
    Sponsored By: Agilent
  • MAY 09, 2019 01:30 PM PDT
    Speaker: Liz Worthey, PhD
  • Progress in Genome Editing Including Single Base Editing and Application
  • MAY 08, 2019 09:00 AM PDT
    Speaker: Manuel Kaulich, PhD
  • Polygenic Risk Scores: PheWas and GWAS and Utility of Biobank Information
  • MAY 09, 2019 09:00 AM PDT
    Polygenic Risk Scores: PheWas and GWAS and Utility of Biobank Information
    Speaker: Guillaume Paré, MD, MSc, FRCPC
    Sponsored By: Illumina
  • Chromosomal Instability, Somatic Cell Recombination and Genomic Stability
  • MAY 09, 2019 10:30 AM PDT
    Speaker: Jerold Chun, MD, PhD
Speakers

  • George Church, PhD
    Professor of Genetics, Director of the Center for Computational Genetics, Harvard Medical School
    Biography
      George M. Church, PhD '84, is professor of genetics at Harvard Medical School, a founding member of the Wyss Institute, and director of PersonalGenomes.org, the world's only open-access information on human genomic, environmental, and trait data. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all "next generation sequencing" methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications - including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. Church is director of IARPA & NIH BRAIN Projects and National Institutes of Health Center for Excellence in Genomic Science. He has coauthored 450 papers, 105 patents, and one book, "Regenesis". His honors include Franklin Bower Laureate for Achievement in Science, the Time 100, and election to the National Academies of Sciences and Engineering.
    • Michael Snyder, PhD
      Professor and Chair, Genetics, Director, Stanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine
      Biography
        Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.
      • Gillian Browne, PhD
        Global Market Development Scientist, Gene Editing and Novel Modalities, MilliporeSigma
        Biography
          Gillian received a BSc in Biomedical Sciences, followed by a PhD in Cellular and Molecular Cancer Biology from the University of Ulster in the UK. Subsequently, she pursued almost five years of postdoctoral research in the United States utilizing a wide variety of molecular biology techniques, and co-authored 13 peer reviewed publications in the field of gene regulation and cancer biology. Her work has enabled other scientists and colleagues further research in the field of genetics, and today she serves as a strategic Global Market Development Scientist and business partner for the commercial teams as at MilliporeSigma, the Life Science business of Merck, KGaA, Darmstadt, Germany and to its gene editing customers around the world.
        • Jerold Chun, MD, PhD
          Professor and Senior Vice President, Sanford Burnham Prebys Medical Discovery Institute
          Biography
            Jerold Chun, MD, PhD, is Professor and Senior Vice President of Neuroscience Drug Discovery at Sanford Burnham Prebys Medical Discovery Institute (SBP). He received his MD and PhD (Neuroscience) degrees through the Medical Scientist Training Program at Stanford University School of Medicine. He moved east as a Helen Hay Whitney Postdoctoral Fellow at the Whitehead Institute for Biomedical Research, MIT. Dr. Chun then joined the faculty at the UCSD School of Medicine, where he became Professor of Pharmacology and Neurosciences and directed the Neurosciences Graduate Program. He subsequently became Department Head of Molecular Neuroscience at Merck Research Laboratories before returning to academia as Professor at The Scripps Research Institute and adjunct Professor at UCSD, leading to his current position. He has made important contributions to our understanding of the brain and its diseases, including the discovery of genomic mosaicism and somatic gene recombination in the brain and its involvement in the most common forms of Alzheimer's disease with relevance to other brain diseases. In separate work, he identified the first lysophospholipid receptor, which is part of a growing class of lipid receptors that underlie new neuroscience medicines (e.g., fingolimod and siponimod for Multiple Sclerosis) and understanding of other diseases, including hydrocephalus, schizophrenia, neuropathic pain, and fibrosis. Dr. Chun has authored more than 300 scientific publications, has been recognized in Thomson Reuters' World's Most Influential Scientific Minds citation list, and is a member of numerous advisory, review, and editorial boards in both academia and industry.
          • Michelle Ding, M.S.
            R&D Scientist, MilliporeSigma
            Biography
              Michelle has extensive R&D and product development experiences across different industries. She started her career at Bayer Crop Science (formerly Monsanto), developing new agricultural traits for insect control. After joining MilliporeSigma in 2015, her research focused on the function of cutting-edge genome editing tools. She led the research on two novel CRISPR technologies, "proxy-CRISPR" and "CRISPR-chrom," which have been published in Nature Communications and The Crispr Journal. Michelle earned her B.S. in Biotechnology from Nanjing Agricultural University and M.S. in Cellular and Molecular Biology from University of Missouri, St. Louis.
            • Kevin Holden, PhD
              Head of Science, Synthego
              Biography
                Kevin Holden is Head of Science at Synthego in Redwood City, California. He is part of a team responsible for integrating synthetic biology workflows, such as CRISPR genome engineering, into novel automation platforms and oversees academic and industrial collaborations with key opinion leaders in the CRISPR community. He has over 10 years of biotechnology experience that includes collaborative research in synthetic biology and genome engineering. Kevin earned his PhD in Microbiology from University of California, Davis. He is originally from the UK and immigrated to the US in his youth.
              • Yanfang Jiang, PhD
                Senior R&D Scientist, MilliporeSigma
                Biography
                  Dr. Yanfang Jiang obtained her PhD degree in microbiology from Department of Microbiology, University of Illinois at Urbana-Champaign, in the laboratory of Dr. John E. Cronan, who is a member of the National Academy of Sciences. Her thesis work focused on lipid and fatty metabolism and fatty acid derived cofactors in bacteria. She completed her postdoctoral training in Washington University in St. Louis, worked on glucose sensing and transport in yeast S. cerevisiae with Dr. Mark Johnston in the Department of Genetics and Center for Genome Sciences. She later worked in Dr. David Wang's laboratory in the Department of Molecular Microbiology in Washington University, involved in discovery and characterization of the first viral infection in nematodes. Dr. Jiang joined the Genome Engineering R&D Group in MilliporeSigma in October 2015 and has been primarily working on developing CRISPR-Cas9 protein products.
                • Manuel Kaulich, PhD
                  CSO, Vivlion
                  Biography
                    Dr. Manuel Kaulich studied biotechnology and molecular life science at the University of Lübeck and obtained his PhD in the laboratory of Erich A. Nigg at Max Planck Institute of Biochemistry in Martinsried (Germany) and the Biozentrum in Basel (Switzerland), respectively. In 2011 he moved to the group of Steven F. Dowdy at the University of California in San Diego, where he first became interested in gene editing technologies. Since December 2015, Manuel is an independent group leader at the Institute of Biochemistry II at Goethe University Frankfurt. Manuel's academic interest lies in cell cycle entry regulation in the context of malignancy. He also developed a strong interest in the CRISPR/Cas9 and rAAV gene editing technologies and has developed technologies to efficiently perform targeted gene replacement in human cells. He is the lead inventor of the 3Cs technology which forms the key of Vivlion's IP portfolio. Together with Ivan Dikic, Manuel Kaulich heads the Frankfurt CRISPR/Cas9 Screening Center (FCSC) at Institute of Biochemistry II. This academic center serves the local research community with technical and bioinformatical expertise to perform gene knockouts for functional studies as well as large scale genome-wide and hypothesis-driven CRISPR/Cas-based screenings.
                  • Mark Kiel, MD, PhD
                    Co-Founder and Chief Science Officer, Genomenon
                    Biography
                      Dr. Mark Kiel is Co-Founder and Chief Science Officer at Genomenon, where he oversees the company's scientific direction and product development. After spending 15 years preparing for a life of academic research, Mark became convinced that revolutionary change in genomics was more likely to emerge out of industry. In 2014, he founded Genomenon - a life science IT company addressing the challenge of connecting doctors with evidence in the literature to help diagnose patients with genetic diseases and cancer.
                    • Jonas Korlach, PhD
                      Chief Scientific Officer, Pacific Biosciences
                      Biography
                        Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company's eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University. Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator "Champion of Change." He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.
                      • Karen Miga, PhD
                        Assistant Research Scientist, Department of Biomolecular Engineering, University of California, Santa Cruz
                        Biography
                          Dr. Miga is a satellite DNA biologist based out of UC Santa Cruz. As an Assistant Research Scientist at the UCSC Genomics Institute and the co-lead of the Telomere-to-Telomere (T2T) Consortium, she works on the forefront of long-read sequencing technologies to generate telomere-to-telomere reference quality assemblies of human chromosomes. Her research program combines innovative computational and experimental approaches to produce the high-resolution sequence maps of human centromeric and pericentromeric DNAs. In doing so, she is uncovering a new source of genetic and epigenetic variation in the human population, which is useful to investigate novel associations between genotype and phenotype of inherited traits and disease. During her doctorate work, under the mentorship of Huntington Willard at Duke University, she gained expertise in human alpha satellite DNA sequence structure and evolution. While a postdoctoral scholar with David Haussler at the University of California in Santa Cruz, Dr. Miga advanced long-read sequencing strategies and satellite DNA graphs to advance our understanding of human centromeric satellites.Her team presented the first linear map of a human centromere on the Y chromosome, and she is working within the T2T Consortium to ensure high-quality, experimentally validated linear assemblies are available for all human centromeric regions.
                        • Devendra Mistry, PhD
                          Senior Field Application Scientist, QIAGEN Advanced Genomics
                          Biography
                            Devendra (Dev) received his PhD from University of California San Diego(UCSD) Biomedical Sciences graduate program and did postdoctoral studies under both academic and pharmaceutical settings. During his post-doctoral studies, he focused on cellular mechanisms regulating stem cells and cancer stem cells through next-gen sequencing data generation, analysis, interpretation and mining. Dev joined QIAGEN as a field application scientist in 2015. In the past 3 years, he has provided trainings to many pharma, biotech, academic and government investigators for different QIAGEN bioinformatics software. In addition, he has helped many of these users troubleshoot problems with their existing workflows and design new workflows.
                          • Guillaume Paré, MD, MSc, FRCPC
                            Associate Professor, Director, Genetic and Molecular Epidemiology Laboratory, McMaster Genome Institute
                            Biography
                              Guillaume Pare is an Associate Professor and University Scholar, Dept. of Pathology & Molecular Medicine at McMaster University and Director of the Genetic and Molecular Epidemiology Laboratory. He was recently inducted as a member into the Royal Society of Canada's College of New Scholars, Artists and Scientists. In 2018, AHA selected his publication (Theriault et al., Circ Genom Precis Med 11:e001849, 2018) as one of the 'Top 10 Advances in Cardiovascular Research in 2018'. Dr. Pare currently holds a Canada Research Chair in Genetic & Molecular Epidemiology, as well as a CISCO Professorship. His clinical interests are centered on lipoprotein disorders, obesity and cardiovascular disease prevention. His corresponding research interests are in cardiovascular genetics, biomarker development and pharmacogenomics. These interests have led to expertise in bioinformatics, high-throughput biology and genetic epidemiology. Since joining McMaster University in 2009, Dr. Pare has published over 190 original contributions in peer-reviewed journals, all related to his research program in cardiovascular disease and genetics. These include first or last authored articles in the NEJM, Lancet (comment), Circulation, EHJ, Stroke, JACC, PLoS Genetics, Circulation Genetics and Scientific Reports. Collectively, he has published 207 peer-reviewed manuscripts, which have been cited over 21,000 times.
                            • John Quackenbush, PhD
                              Professor of Computational Biology and Bioinformatics, Chair of the Department of Biostatistics, Harvard University, Dana-Farber Cancer Institute
                              Biography
                                John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John's PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. He currently directs the Computational Biology and Quantitative Genetics MS program and is PI of the BD2K Training Grant at HSPH. John's research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
                              • Erle Robertson, PhD
                                Harry P. Schenck Endowed Chair Professor, Vice-Chair, Department of Otorhinolaryngology, Perelman School of Medicine, University of Pennsylvania
                                Biography
                                  Erle S. Robertson obtained his Dr. Robertson received his doctorate degree from Wayne State University in Microbiology and Molecular Genetics where he studied interaction of the T-phages with bacterial hosts by mapping their infection proteome. He then completed his post-doctoral studies at Harvard Medical School and Brigham and Women's Hospital in the Department of Medicine/Infectious Disease Division as a Cancer Research Institute Fellow and an Leukemia and Lymphoma Society Special Fellow. There he studied the role of EBV in driving the oncogenic process in human cells using genetic and biochemical approaches. In 1994 he was promoted to Instructor in Medicine and was recruited to the University of Michigan Medical School in 1997. He was promoted to Associate Professor with tenure in 2002 in the Department of Microbiology. He was recruited to the Perelman School of Medicine with tenure in 2002, quickly achieving the rank of Full Professor with tenure in 2006. His awards include the Scholar Award of the Lymphoma and Leukemia Society, named Fellow of the American Academy of Microbiology, Fellow of the American Association for the Advancement of Sciences, and Fellow of the College of Physicians of Philadelphia. He was also selected as a Penn Fellow by the President and Provosts office of the University in recognition of his contribution to the cross-disciplinary activities that can bridge and enhance greater activities related to research and scholarship between different schools at Penn. In 2016, Dr. Robertson was recruited to the Department of Otorhinolaryngology to serve as Vice-Chair for Research and Director of Head and Neck Sciences in the Department of Otorhinolaryngology - Head and Neck Surgery. Since joining the department, Dr. Robertson has contributed significantly to building an internationally recognized research program in head and neck sciences with increased interactions and collaborations with the Abramson Cancer Center and across our collective clinical and basic science departments.
                                • Jonathan Shaffer, MBA, PhD
                                  Associate Director, NGS Assay Technologies, QIAGEN
                                  Biography
                                    Dr. Shaffer joined QIAGEN in 2009 and has since worked with various technology development groups, the most recent being RNA NGS technologies. He received his Ph.D. in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine in 2008 where his research focused on determining the mechanisms that regulate non-receptor tyrosine kinase expression and activity. Dr. Shaffer did his postdoctoral training at SABiosciences Corporation, now part of QIAGEN. In 2018 he received his M.B.A. from Julius Maximilians University of Wurzburg. Currently, Dr. Shaffer is Associate Director for NGS Assay Technology Research & Development at QIAGEN.
                                  • Liz Worthey, PhD
                                    Faculty Investigator, HudsonAlpha Institute for Biotechnology
                                    Biography
                                      Liz Worthey, PhD, is a faculty investigator and the director for software development and informatics at the HudsonAlpha Institute for Biotechnology. She is interested in developing new tools for interpreting genomic data. Worthey leads her team in supporting the informatics goals of the institute as well as the clinical mission to provide definitive diagnoses for patients. Worthey received her PhD in genetics from Imperial College London in 2003 and completed her postdoctoral fellowship at the Seattle Biomedical Research Institute at the University of Washington, working on both eukaryotic genomics and other high throughput "omics" projects. In 2008, after working as a project manager for Merck & Co., Worthey joined the Medical College of Wisconsin (MCW) as senior research scientist and became an assistant professor of pediatric genomics in 2010. Worthey became director of genomic informatics for the Human and Molecular Genetics Center at MCW in 2012. She also holds an adjunct assistant professorship in the computer science department at the University of Wisconsin - Milwaukee and adjunct assistant professor positions within the department of pediatrics and department of genetics at the University of Alabama at Birmingham. Her lab develops and applies genomic and informatics methods in order to identify and study molecular variation in human disease. A particular focus is on diagnosis in patients with rare or undiagnosed disease. They develop a variety of tools and methods to study the impact of variation and are interested in identifying and studying not only causal variation, but also genetic modifiers of disease initiation, progression, and/or disease outcome.
                                    • Tao Wu, PhD
                                      Assistant Professor, CPRIT Scholar for Cancer Research, Department of Molecular and Human Genetics, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
                                      Biography
                                        Dr. Tao Wu received his B.S. from Nankai University a leading academic institution in China. In his last year at college, his reading of "What Is Life? The Physical Aspect of the Living Cell" (by physicist Erwin Schrödinger, 1944) inspired him to pursue a career in deciphering the physical principles of biological systems. In 2003, Tao joined the Institute of Biophysics, Chinese Academy of Sciences (Beijing), where he was mentored by Prof. Runsheng Chen a founding father of genomics and bioinformatics research in China. Under his tutelage, Tao started to investigate the function and mechanisms of genome "Dark Matter" (i.e., non-coding RNAs) in C. elegans and human cancer models. During this training, Tao developed expertise in bioinformatics, genomics, and systems biology. He built one of the first non-coding-RNA-protein interaction databases (NPInter) [1] and subsequently developed a linear time-ordered computational model which was used to estimate the cell states during differentiation, reprogramming, or tumorigenesis [2-4]. To pinpoint the regulatory mechanism of non-coding RNAs during development in C. elegans, Tao led a project to systematically characterize the elements of non-coding RNAs transcriptional regulation with the DNaseI-Hypersensitive-Sites method in 2008, presaging the larger efforts as part of the modENCODE projects [5]. In the last year at graduate school, Tao began to tackle the question of how do cells commit to different cell fates with the same genomic DNA information? In 2010, Tao joined the newly established lab of Dr. Andrew Xiao at Yale to study epigenetics as a potential answer to this question. There, Tao utilized biochemistry and epigenetics approaches to complement his genomics expertise to tackle this problem. He applied these approaches to address the fundamental questions in the context of stem cell and Induced Pluripotent Stem Cell (iPSC) reprogramming. Identifying better biomarkers for assessing iPSC quality is an important goal for moving to clinical application. Instead of using transcriptional profiling or well-known histone modification markers, Tao discovered that an "epigenomic pattern mutation" of histone variants is essential for explaining the developmental variability of iPSCs. Tao discovered H2A.X, a histone variant of H2A that is usually involved in the DNA damage repair could mediate repression of extraembryonic lineage gene expression in embryonic stem cells (ESCs). He found that genomic deposition defects (called "epigenomic pattern mutation") frequently occur in the low-quality iPSC lines, whereas its deposition recapitulates the ESC's pattern in the high-quality iPSCs. The epigenomic pattern mutation of H2A.X leads to aberrant expression of extraembryonic lineage genes in low-quality iPSCs (which mimics the phenotype of H2A.X-knockout ESCs) and predisposes them to extraembryonic lineage differentiation in vitro and in vivo [6-8]. This work may pave the way for improved clinical application of iPSCs in regenerative medicine. Following up on this discovery, Tao continued to dissect the mechanism of how H2A.X is targeted to specific genomic loci. To identify the unique property of DNA at H2A.X-nucleosome deposition sites, he developed a novel variation of ChIP-Seq, "SMRT-ChIP", which can simultaneously determine DNA modifications and genomic sequences of histone binding sites. This approach leverages native Chromatin Immunoprecipitation (N-ChIP) and the 3rd generation single-molecule real-time sequencing (SMRT) technology. By in depth analysis of H2A.X SMRT-ChIP data, he enjoyed a true "Eureka Moment". Tao discovered a novel mammalian DNA modification, DNA N6-methyladenine (N6-mdA). This is a form of DNA methylation that had not yet been detected in mammals [9, 10]. Tao also showed that ALKBH1 is major demethylase of N6-mdA, and the main function of N6-mdA is targeting and silencing evolutionarily younger LINE-1 retrotransposons in ESCs [9]. The Identification of novel DNA modifications in mammalian genomes is a "holy-grail" question in the epigenetics field. Despite the extensive search by leading labs for over forty years, only 5-methylcytosine (5mC) and its derivatives were known as functional DNA modifications in mammals before 2016. Hence, Tao's work opened a new chapter in mammalian epigenetics and stem cell biology [10]. Importantly, Tao was quickly appreciated the potential link between this DNA rare modification and malignant tumors. Thus, Tao initiated collaborations with leading cancer biology labs to show that while N6-mdA is rare in normal somatic cells, it is greatly enriched in high-grade glioblastoma patients' samples. He hypothesized that N6-mdA may be a mechanism by which cancer stem cells hijacks an early embryological mechanism for adapting to cancer niches and therapeutic resistance. Dr. Wu will take advantage of the state-of-the-art resources of Baylor College of Medicine and the Texas Medical Center cancer community to continue to explore the fundamental epigenetic mechanisms underlying the anti-cancer therapeutic resistance. In addition to the classical pathways adapted by neoplastic cells to resist treatment, the co-opting of epigenetic regulatory processes is increasingly being recognized as an essential contributor to treatment resistance. By combining biochemical, epigenetic, and bioinformatics approaches, Dr. Wu will define new vulnerabilities that can be targeted to overcome therapeutic resistance in cancer treatment.
                                      Posters

                                      POSTER SUBMISSION GUIDELINES

                                      Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


                                      SUBMIT YOUR ABSTRACT

                                      Enter the following information to this Submission Form:

                                      • Poster Title
                                      • Your Name
                                      • Your Institution
                                      • Your Email
                                      • Abstract describing the poster


                                      All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

                                      If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

                                      Questions? Email Posters@LabRoots.com

                                      LabRoots Policy

                                      Sponsored By

                                      For information on becoming a sponsor or exhibitor, please click here.


                                      Committee

                                      To download the Program Committee brochure here.


                                      • Timothy Harris

                                        Since June 2011, Dr. Harris has served as the Senior Vice President of Translational Medicine at Biogen Idec. Dr. Harris has served as the Director of the Advanced Technology Program at SAIC Frederick since 2007 and Chief Technology Officer for SAIC Frederick since 2008. Prior to ...

                                        See more See less
                                      • Fritz Sedlazeck

                                        Dr. Fritz Sedlazeck completed his PhD in 2012 in the group of Dr. Arndt von Haeseler at the Max F. Perutz Laboratory in Vienna. After a two year postdoc, he transitioned to the lab of Dr. Michael Schatz at Cold Spring Harbor Laboratory and later to Johns Hopkins University. Since ...

                                        See more See less
                                      • Jonas Korlach

                                        Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He ...

                                        See more See less
                                      • Shawn Baker

                                        Dr. Shawn C. Baker is the Chief Science Officer and co-founder of AllSeq. Having received his Ph.D. at the University of California - Davis, he started his career as a Research Scientist at Illumina when it was a 15-person startup. After spending several years at the bench ...

                                        See more See less
                                      • Molly McGinniss

                                        Molly McGinniss, MS, LCGC is a Senior Market Development Manager for Illumina's "Healthy Genome Initiatives" team. Her current role focuses on advancing the use of whole genome sequencing in clinical care by providing access and education to healthy individuals through the ...

                                        See more See less
                                      • John Quackenbush

                                        John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John's PhD was in ...

                                        See more See less
                                      • C Jimmy Lin, MD, PhD, MHS

                                        Jimmy Lin, MD, PhD, MHS, is a 2012 TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Partnering with 18 of the top medical ...

                                        See more See less
                                      • Agnieszka Caruso

                                        Agnieszka is currently a Staff Scientist and Laboratory Manager at TessArae, LLC in Sterling, VA, USA. She obtained her PhD at the University of Queensland in Australia in a field of biochemistry, and subsequently worked as a post-doctoral fellow at Queen's University of Belfast ...

                                        See more See less
                                      Help

                                      General LabRoots Questions

                                      For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                      Contact us

                                      Virtual Events and Webinars

                                      Supported Configurations

                                      • Operating System Internet Explorer Firefox Chrome Safari
                                        Vista IE8+ FF10+ Chrome15+
                                        Windows 7 IE8+ FF10+ Chrome15+
                                        Windows 8 IE10 FF10+ Chrome15+
                                        Mac OS X   FF10+ Chrome15+ Safari5.1+
                                      • Cookie settings: session cookies enabled
                                      • Browser configuration must have JavaScript enabled
                                      • Adobe Flash player 10.2 or later

                                      To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                      Internet Connection

                                      • A minimum of 100Kbps is recommended for audio-only events
                                      • A minimum of 300Kbps is recommended for speaker on-video events

                                      Computer Equipment

                                      • Screen Resolution: Minimum 1024x768
                                      • Video Card: 65,000 colors minimum
                                      • Sound card and speakers (or headphones) for hearing webcast in full format
                                      • Audio Card: 16-bit minimum
                                      • RAM: 512MB of free RAM

                                      Firewall Protocol

                                      • HTTP on port 80 or HTTPS on port 443
                                      • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                      • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                      Work-At-Home Attendees

                                      • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                      For A Seamless Experience

                                      When using a mobile device, FREE Mobile Apps are available:

                                      - For viewing Webinars:

                                      - For viewing Virtual Events

                                      Attendee Guide

                                      • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                      Virtual Event and Webinar Support:

                                      Continuing Education (CME/CE) Support

                                      Loading Comments...
                                      Show Resources